Michael K. Brawer
#155,781
Most Influential Person Now
Michael K. Brawer's AcademicInfluence.com Rankings
Michael K. Brawerengineering Degrees
Engineering
#6490
World Rank
#7821
Historical Rank
Biomedical Engineering
#583
World Rank
#593
Historical Rank
Michael K. Brawerphilosophy Degrees
Philosophy
#8814
World Rank
#12267
Historical Rank
Logic
#5829
World Rank
#7270
Historical Rank
Download Badge
Engineering Philosophy
Michael K. Brawer's Degrees
- PhD Biomedical Engineering Stanford University
Why Is Michael K. Brawer Influential?
(Suggest an Edit or Addition)Michael K. Brawer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Radical prostatectomy versus observation for localized prostate cancer. (2012) (1359)
- Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. (1998) (1176)
- The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (1996) (732)
- Prostatic Intra‐Epithelial Neoplasia and Early Invasion in Prostate Cancer (1987) (517)
- Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity (1994) (442)
- Follow‐up of Prostatectomy versus Observation for Early Prostate Cancer (2017) (430)
- Screening for prostatic carcinoma with prostate specific antigen. (1992) (392)
- Comparison of microscopic vascularity in benign and malignant prostate tissue. (1993) (341)
- Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. (2000) (326)
- Keratin immunoreactivity in the benign and neoplastic human prostate. (1985) (294)
- Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. (1995) (290)
- The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. (1993) (230)
- Repeat prostate needle biopsy: who needs it? (1995) (223)
- Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. (1998) (198)
- Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. (2014) (194)
- The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. (1994) (186)
- Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. (1994) (183)
- Measurement of complexed PSA improves specificity for early detection of prostate cancer. (1998) (168)
- Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. (1991) (164)
- Topography of neovascularity in human prostate carcinoma (1995) (159)
- Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. (1997) (159)
- Screening for prostatic carcinoma with prostate specific antigen: results of the second year. (1993) (150)
- Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. (2000) (144)
- Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. (2003) (137)
- Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. (1991) (134)
- Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort (2015) (127)
- Quantitative microvessel density: A staging and prognostic marker for human prostatic carcinoma (1996) (127)
- The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. (2009) (121)
- Prostate‐specific antigen: Current status (1999) (115)
- The significance of isoechoic prostatic carcinoma. (1994) (109)
- Expression of metalloproteinase genes in human prostate cancer (2005) (108)
- Prostatic intraepithelial neoplasia: a premalignant lesion. (1992) (102)
- The prostate cancer intervention versus observation trial (PIVOT). A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer (1995) (100)
- Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. (1989) (99)
- Attitudes and use of complementary medicine in men with prostate cancer. (2002) (97)
- Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry (2014) (97)
- Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. (1997) (96)
- Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. (2002) (92)
- Microvascularity in benign prostatic hyperplasia (1995) (91)
- Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. (2003) (88)
- Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. (2002) (87)
- Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. (1993) (87)
- Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. (1999) (87)
- Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer (1998) (83)
- Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). (1997) (80)
- Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates (1989) (78)
- Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. (2005) (76)
- The effect of digital rectal examination on serum levels of prostatic-specific antigen. (1988) (75)
- Serum basic fibroblast growth factor in men with and without prostate carcinoma (1995) (72)
- Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared. (1987) (72)
- Prostatic intraepithelial neoplasia: an overview. (2005) (71)
- Morphometric quantitation of stromain human benign prostatic hyperplasia (1994) (71)
- Focal Fatty Change of the Liver, a Hitherto Poorly Recognized Entity (1980) (70)
- Vasectomy and prostate cancer: a case-control study in a health maintenance organization. (1996) (67)
- The prostate cancer intervention versus observation trial (1994) (64)
- Prostate-specific antigen in management of prostatic carcinoma. (1989) (63)
- The effect of prostate volume on the yield of needle biopsy. (1998) (62)
- Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer Prior to Initial Prostate Biopsy. (2019) (61)
- Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. (1991) (61)
- Sialyl-Lewis(x) and related carbohydrate antigens in the prostate. (1995) (61)
- Prostate-specific antigen. (2001) (60)
- Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. (2016) (58)
- Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. (1998) (56)
- Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer (2014) (55)
- Vasectomy and risk of prostate cancer. (1999) (54)
- Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. (2000) (53)
- Comparison of 3 investigational assays for the free form of prostate specific antigen. (1998) (48)
- The relationship of basement membrane to histologic grade of human prostatic carcinoma. (1989) (48)
- A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. (2017) (48)
- Prostate‐specific antigen and premalignant change: Implications for early detection (1989) (47)
- The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. (1993) (46)
- Prostate-Specific Antigen: Its Role in Early Detection, Staging, and Monitoring of Prostatic Carcinoma (1989) (45)
- Morphometric quantitation of stroma in human benign prostatic hyperplasia. (1994) (44)
- Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. (1997) (44)
- A neurocomputational model for prostate carcinoma detection (2003) (43)
- Testosterone replacement in men with andropause: an overview. (2004) (43)
- Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. (2005) (42)
- Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. (2001) (42)
- Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. (1997) (41)
- Prognostic utility of biopsy‐derived cell cycle progression score in patients with National Comprehensive Cancer Network low‐risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance (2017) (41)
- Urinary prostate specific antigen levels after radical prostatectomy. (1994) (40)
- Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. (2011) (40)
- Screening for prostate cancer. (2000) (39)
- Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. (1998) (38)
- Focal fatty change of the liver, a hitherto poorly recognized entity. (1980) (37)
- Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program (2003) (37)
- Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. (1994) (35)
- Assay variability in serum prostate‐specific antigen determination (1995) (34)
- Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer. (1989) (34)
- Multicenter comparison of the diagnostic performance of free prostate-specific antigen. (1996) (34)
- Hormonal therapy for prostate cancer. (2006) (33)
- Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6–4.0 ng/mL range of total PSA (2004) (33)
- Variation in measurement of prostate-specific antigen: importance of method and lot variability. (1995) (32)
- Prostate specific antigen. A review. (1991) (32)
- Role of transrectal ultrasound and prostate biopsy (1996) (29)
- Osteogenic sarcoma after retinoblastoma radiotherapy. (1979) (29)
- How to use prostate-specific antigen. (1994) (28)
- Prostate cancer detection. (1994) (28)
- Prostate-specific antigen: Critical issues (1994) (28)
- Age‐specific prostate‐specific antigen: A reassessment (1996) (26)
- Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer. (1999) (25)
- Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. (2002) (25)
- Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. (1995) (24)
- Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. (2018) (23)
- Editorial: Prostate Cancer Detection (1994) (22)
- Prostatic intraepithelial neoplasia: a lesion that may be confused with cancer on prostatic ultrasound. (1989) (21)
- Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. (2002) (21)
- Prostatic abscess owing to anaerobic bacteria. (1987) (20)
- Chemoprevention for prostatic intraepithelial neoplasia. (1996) (20)
- Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. (2016) (20)
- Comparison of three commercial PSA assays: Results of restandardization of the Ciba Corning method (1997) (20)
- Papaverine-induced fibrosis of the corpus cavernosum. (1989) (20)
- Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for. (1996) (19)
- New relationships between prostatic intraepithelial neoplasia and prostatic carcinoma (1992) (19)
- Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. (2019) (18)
- Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. (1995) (18)
- Prostate cancer: serum and tissue markers. (2001) (17)
- Prostatic abscess after transrectal ultrasound guided biopsy. (1991) (16)
- Prostate Cancer: Where We Have Been, Where We Are, Where We Are Going (2000) (15)
- PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia. (1993) (15)
- PSA in the screening, staging and follow-up of early-stage prostate cancer (1989) (14)
- Prostatic intraepithelial neoplasia and prostate-specific antigen (2004) (14)
- The evolution of hormonal therapy for prostatic carcinoma. (2001) (14)
- Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? (2002) (13)
- The Influence of Prostate Volume on Prostate Cancer Detection (2002) (13)
- Mucinous adenocarcinoma probably arising in the renal pelvis and ureter: a case report. (1980) (12)
- Clinical usefulness of assays for complexed prostate-specific antigen. (2002) (12)
- Prostatic intraepithelial neoplasia: significance and management. (1996) (11)
- Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. (2003) (11)
- Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. (2003) (11)
- Papillary adenocarcinoma of ureter. (1982) (11)
- Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer. (2004) (11)
- Chemoprevention for prostate cancer (1995) (11)
- Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience. (2001) (11)
- Prostate cancer: epidemiology and screening. (2000) (11)
- Survival of full-thickness skin grafts over avascular defects. (1980) (10)
- Endobronchial metastases from prostatic carcinoma. (1988) (10)
- Chemoprevention strategies in the prostate: an overview. (2002) (10)
- A schema for teaching differential diagnosis. (1988) (10)
- Laboratory studies for the detection of carcinoma of the prostate. (1990) (10)
- Prostatic intraepithelial neoplasia: A premalignant lesion (1992) (9)
- Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. (2015) (9)
- Differences in prostate size between patients from university and Veterans Affairs medical center populations (1999) (8)
- Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101). (2007) (8)
- Prostate cancer in relation to the use of electric blanket or heated water bed. (1999) (8)
- Prostate cancer: risk assessment and diagnostic approaches. (2001) (7)
- Perspectives on prostate cancer diagnosis and treatment: a roundtable. (2001) (7)
- Workgroup 4: Exploration of new pathologic factors in terms of potential for prognostic significance and future applications (1996) (7)
- Androgen deprivation and other treatments for advanced prostate cancer. (2001) (6)
- Prolaris: A novel genetic test for prostate cancer prognosis. (2013) (6)
- Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA. (2010) (6)
- Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. (1996) (6)
- Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice (2019) (5)
- Challenges with luteinizing hormone-releasing hormone agonists: flare and surge. (2004) (5)
- COMPLEXED PROSTATE SPECIFIC ANTIGEN (cPSA): RESULTS OF A MULTICENTER BIOPSY EXPERIENCE (1999) (5)
- MP79-17 VALIDATION OF A 46-GENE CELL CYCLE PROGRESSION (CCP) RNA SIGNATURE FOR PREDICTING PROSTATE CANCER DEATH IN A CONSERVATIVELY MANAGED WATCHFUL WAITING NEEDLE BIOPSY COHORT (2014) (4)
- Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. (2003) (4)
- Massive lymphocele following pelvic lymphadenectomy for staging of prostatic cancer. (1989) (4)
- CCP score and risk stratification for prostate cancer patients at biopsy. (2014) (4)
- Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. (2015) (4)
- Editorial: Prostate Cancer (1997) (4)
- What will replace TURP? (1992) (4)
- Testosterone replacement therapy for a man with prostate cancer. (2004) (4)
- LONG-TERM STABILITY OF COMPLEX PROSTATE SPECIFIC ANTIGEN (PSA) IN FROZEN SERUM (1999) (4)
- Prostatectomy versus Observation for Early Prostate Cancer. (2017) (3)
- Early diagnosis and staging of prostate cancer. (2003) (3)
- Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. (2021) (3)
- The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. (2021) (3)
- Molecular Forms of Prostate-Specific Antigen for Prostate Cancer Detection (2003) (3)
- 1874: External Validation of the Prostate Cancer Risk Calculator (2007) (3)
- Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA (2003) (3)
- 161 DETERMINATION OF CLINICAL CHARACTERISTICS FOR MEN ON ADT AS RELATED TO BASELINE SERUM TESTOSTERONE VALUES (2011) (3)
- 1565: Initial Results of a Randomized Multi-Center Trial Comparing the Efficacy and Safety of Indigo Optima Laser Treatment with Tamsulosin in Men with LUTS and BPH (2005) (3)
- Clinical Evidence: Non-metastatic prostate cancer. (1999) (3)
- Prostate ultrasonography in normal and benign conditions (1992) (3)
- Staging for prostate cancer. (1994) (3)
- Clinical utility study of confirms mdx for prostate cancer in a community urology practice. (2019) (2)
- MP79-15 PROGNOSTIC UTILITY OF THE CELL CYCLE PROGRESSION (CCP) SCORE GENERATED FROM NEEDLE BIOPSY IN MEN TREATED WITH PROSTATECTOMY (2014) (2)
- Update on the Treatment of Prostate Cancer: The Role of Adjuvant Hormonal Therapy (2004) (2)
- Panel II: Diagnosis and markers in prostate cancer (1992) (2)
- Stratification of risk for patients with prostate cancer at biopsy using CCP score. (2013) (2)
- PROSTATE NEEDLE BIOPSY IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN (PSA) LESS THAN 4.0 ng/ml: THE ROLE OF COMPLEX PSA (cPSA) (1999) (2)
- Radical prostatectomy and observation did not differ for mortality in localized prostate cancer (2012) (2)
- Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7. (2014) (2)
- PROGNOSTIC UTILITY OF BIOPSY‐DERIVED CELL CYCLE PROGRESSION SCORE IN PATIENTS WITH NCCN LOW‐RISK PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE: MP28‐13 (2017) (2)
- Caring for Patients With Prostate Cancer Who Are BRCA Positive. (2016) (2)
- The effect of cell cycle progression (CCP) score on treatment decisions in prostate cancer: Results of an ongoing registry trial. (2014) (2)
- Prostate‐specific antigen density and velocity measurements in the diagnosis of prostate cancer (1993) (2)
- New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the american society of clinical oncology, may 30-june 3, 2008, chicago, IL. (2008) (2)
- Results of a multicenter prospective evaluation of complexed PSA (2002) (2)
- Prostatic intraepithelial neoplasia and prostate-specific antigen. (1993) (2)
- Urology Update from Jackson Hole: Highlights from the 3rd Annual Jackson Hole Summer Urologic Conference July 28-August 3, 2001, Jackson Hole, WY. (2002) (1)
- [Non-metastatic prostate carcinoma]. (2001) (1)
- Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. (2014) (1)
- THE IMPACT OF CLINICAL CCP TESTING IN MEN WITH LOCALIZED PROSTATE CANCER FOR EXPANDING THE POPULATION OF MEN ELIGIBLE FOR ACTIVE SURVEILLANCE: PD28‐02 (2017) (1)
- Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy. (2014) (1)
- 1206 MEN WITH ISOLATED HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA (HGPIN) HAVE A HIGH RISK OF PROSTATE CANCER IN LONG-TERM FOLLOW-UP: RESULTS FROM A PROSPECTIVE MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED PROSTATE CANCER PREVENTION TRIAL., (2011) (1)
- PD32-11 SIGNIFICANT REDUCTION IN THERAPEUTIC BURDEN FROM USE OF CCP TEST IN TREATMENT DECISIONS AMONG NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A LARGE PROSPECTIVE REGISTRY (2015) (1)
- A COMPARISON OF THREE DIFFERENT MANUFACTURERS' FREE TO TOTAL PROSTATE SPECIFIC ANTIGEN (F/T PSA) ASSAYS (1999) (1)
- Markers of premalignant and early malignant lesions (1992) (1)
- RADICAL PROSTATECTOMY VERSUS OBSERVATION FOR EARLY PROSTATE CANCER: FOLLOW‐UP RESULTS OF THE PROSTATE CANCER INTERVENTION VERSUS OBSERVATION TRIAL (PIVOT): PNFLBA‐11 (2017) (1)
- Treatment of renal cell carcinoma by extracorporeal partial nephrectomy and autotransplantation using splenic vascular anastomosis. (1991) (1)
- The Management of Radiation Failure in Prostate Cancer (2002) (1)
- 1265: International Multi-Center Comparison of Complexed Prostate Specific Antigen (CPSA) with Total PSA, Percent CPSA, and Percent free PSA (2004) (1)
- Predicting outcomes of therapy for prostate carcinoma patients (1998) (1)
- Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. (2009) (1)
- Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA. (2007) (1)
- Prostate Cancer (2003) (1)
- 535: Relationships of Life Style with PSA, Testosterone and Cholesterol in a Large Cohort of Men Screened or Prostate Cancer (2006) (1)
- Complexed PSA: the newest advance in PSA testing. (1999) (1)
- Editorial Comment: A Comparison of the Free Fraction of Serum Prostate Specific Antigen in men with Benign and Cancerous Prostates (1996) (1)
- Vasectomy and Risk of Prostate Cancer 1 (2000) (1)
- MP24-02 CLINICAL UTILITY OF CONFIRMMDX FOR PROSTATE CANCER IN A COMMUNITY UROLOGY PRACTICE (2019) (1)
- Cell Cycle Progression (CCP) Score Significantly Predicts PSA Failure After EBRT (2013) (1)
- Commentary on: Radical Prostatectomy Versus Observation for Localized Prostate Cancer (2012) (1)
- Patient NCCN risk classification based on combined clinical cell cycle risk (CCR) score. (2017) (1)
- EVALUATING THE PROGNOSTIC UTILITY OF THE CCP SCORE FOR PREDICTING PROSTATE CANCER AGGRESSIVENESS IN AFRICAN AMERICAN MEN: MP28‐19 (2017) (1)
- Update: prostate cancer. (1990) (1)
- MP02-20 THE CCP SCORE PROVIDES SIGNIFICANT PROGNOSTIC INFORMATION IN GLEASON SCORE < 7 PATIENTS (2016) (1)
- Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. (2015) (1)
- New technique for repair of rectal injury. (1993) (1)
- PREDICTION OF MISSED CARCINOMA ON PROSTATE BIOPSY IS ENHANCED WITH ARTIFICIAL NEURAL NETWORKS (1999) (1)
- Evaluation of a predefined AS threshold in a large cohort of men with localized prostate cancer. (2018) (1)
- Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. (2002) (1)
- Best of the 2008 AUA Annual Meeting (2008) (0)
- Cell cycle progression score to modify treatment decisions in prostate cancer: Results of an ongoing registry trial. (2014) (0)
- Readership survey: reviews in urology. (2001) (0)
- PROSTATE BIOPSY OUTCOME PREDICTION – COMPARISON OF A NOVEL LOGISTIC REGRESSION-BASED MODEL, THE PROSTATE CANCER RISK CALCULATOR AND PSA ALONE (2008) (0)
- Recent Developments in the Metabolic Management of BPH (2005) (0)
- The role of alpha 1-blockade in benign prostatic hyperplasia. (1993) (0)
- Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA. (2012) (0)
- CONTRIBUTIONS Vasectomy and Prostate Cancer : A Case-Control Study in a Health Maintenance Organization (2005) (0)
- Aggressive Urologic Malignancy in Heart Transplant Recipients (2010) (0)
- Advances in the Management of Prostate Cancer: The Emerging Role of ProstaScint® and Quadramet® (2004) (0)
- The role of radiotherapy following radical prostatectomy. (1992) (0)
- Update on the Use of Interstitial Laser Coagulation in the Treatment of Benign Prostatic Hyperplasia (2005) (0)
- The 11th International Prostate Cancer Update (2001) (0)
- Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men. (2019) (0)
- Corrigendum re: "Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)" [Eur Urol 2020;77:713-24]. (2021) (0)
- 778PCOMBINED ANALYSIS OF AN RNA CELL CYCLE PROGRESSION (CCP) SCORE FOR PREDICTING PROSTATE CANCER DEATH IN TWO CONSERVATIVELY MANAGED NEEDLE BIOPSY COHORTS. (2014) (0)
- Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL. (2008) (0)
- Stones, BPH, Renal and Prostate Disease Discussed at Jackson Hole: Highlights from the 19th Annual Jackson Hole Urologic Conference January 23-30, Jackson Hole, Wyo. (1999) (0)
- Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index. (2016) (0)
- 344 Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy (2014) (0)
- Transrectal ultrasonography of the prostate. (1989) (0)
- Diagnosis and markers in prostate cancer. (1992) (0)
- Evaluating the impact of African American ancestry among men with localized prostate cancer treated with radical prostatectomy. (2018) (0)
- A 2-gene mRNA urine test for detection of high-grade prostate cancer prior to initial prostate biopsy (2019) (0)
- MP11-11 META-ANALYSIS OF THE PROGNOSTIC UTILITY OF THE CELL CYCLE PROGRESSION SCORE GENERATED FROM NEEDLE BIOPSY IN MEN TREATED WITH DEFINITIVE THERAPY (2018) (0)
- Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy. (2010) (0)
- Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA. (2016) (0)
- Stat Bite Predictive Value of Prostate Cancer Tests (1993) (0)
- Book Reviews (2002) (0)
- Prostate cancer. (1995) (0)
- New urologic strategies explored at jackson hole: highlights from the 20th annual jackson hole urologic conference january 22-28, 2000, jackson hole, wyo. (2000) (0)
- Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC. (2011) (0)
- A Multicenter Study on the Efficacy and Safety of Interstitial Laser Coagulation Versus alpha-Blockade in Subjects With Symptomatic Benign Prostatic Hyperplasia: Preliminary Results. (2005) (0)
- Author ' s Accepted Manuscript Impact of the CCP test on physician and patient treatment selection for localized prostate cancer (2015) (0)
- CCP Score Stratifies Risk for Prostate Cancer Patients at Biopsy: Initial Commercial Results (2014) (0)
- LHRH Agonists: Contemporary Issues (2004) (0)
- PATIENT NCCN RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE: PD65‐06 (2017) (0)
- Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. (2013) (0)
- 583 TOREMIFENE IMPROVES PSA PROGRESSION FREE SURVIVAL IN CASTRATE MEN WITH DETECTABLE BASELINE PSA LEVELS (2010) (0)
- 16th International Prostate Cancer Update (2003) (0)
- Transrectal Ultrasonography of the Prostate PROSTATIC (0)
- MP79-19 PREDICTING RADICAL PROSTATECTOMY OUTCOME: CCP-CR SCORE OUTPERFORMS PRIMARY GLEASON GRADE AMONG MEN WITH CLINICAL GLEASON <7 WHO ARE UPGRADED TO GLEASON 7 (2014) (0)
- Terazosin in the treatment of obstruction of the lower urinary tract (2005) (0)
- The Effect of Digital Rectal Examination on Serum Prostate Specific Antigen and Acid Phosphatase (1987) (0)
- The Role of Prostate Specific Antigen and Its Variants in Prostate Cancer Screening (2001) (0)
- 1088 - Bacteremic Infection of Penile Prostheses (1987) (0)
- Unravelling the confusions in prostatic disease (1998) (0)
- Management of localized prostate cancer. (2004) (0)
- MP1-10 VALIDATION OF AN ACTIVE SURVEILLANCE THRESHOLD FOR THE CCP SCORE IN CONSERVATIVELY MANAGED MEN WITH LOCALIZED PROSTATE CANCER (2015) (0)
- Pathologic Evaluation Of Non-tumor Renal Tissue Predicts Renal Function Post Radical Nephrectomy (2015) (0)
- MP1-08 PATIENT AUA RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE (2015) (0)
- MP24-04 A 2-GENE MRNA URINE TEST FOR DETECTION OF HIGH-GRADE PROSTATE CANCER PRIOR TO INITIAL PROSTATE BIOPSY (2019) (0)
- Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients. (2015) (0)
- Expression of metalloproteinase in human prostate cancer (1991) (0)
- Letter from the editors of reviews in urology. (2001) (0)
- Correlation of prostate-specific antigen and ultrasonography in the evaluation of patients with carcinoma of the prostate. (1994) (0)
- 16TH INTERNATIONAL PROSTATE CANCER UPDATE Hormonal Therapy for Prostate Cancer (2006) (0)
- Decision tree algorithms for prostate cancer detection Complexed PSA and other significant predictors using CHAID analysis (2002) (0)
- Application of active surveillance threshold to series of samples submitted for commercial testing. (2016) (0)
- Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. (2017) (0)
- Urinary Tract Pathology: An Illustrated Practical Guide to DiagnosisBernsteinJ. and ChurgJ.: Urinary Tract Pathology: An Illustrated Practical Guide to Diagnosis. New York: Raven Press1992: 241. (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael K. Brawer?
Michael K. Brawer is affiliated with the following schools:
